FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4377011619> ?p ?o ?g. }

• W4377011619 endingPage "110787" @default.
• W4377011619 startingPage "110787" @default.
• W4377011619 abstract "Tardive dyskinesia (TD) is a persistent involuntary complex movement disorder that is known to occur with long-term antipsychotic treatment. Despite being a well-recognized complication of this treatment, its symptoms are often masked by the antipsychotic agents, only to become apparent upon reducing or terminating the treatment. In an effort to advance our understanding of TD pathophysiology and to identify potential therapies, the current study aimed to establish an animal model of TD by administering haloperidol to rats and to evaluate the efficacy of fluvoxamine, a selective serotonin reuptake inhibitor (SSRI), in ameliorating TD symptoms. The study compared the behavioral and biochemical parameters of rats that were treated with either fluvoxamine, tetrabenazine, haloperidol, or saline (control group). The biochemical parameters of interest included the brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), superoxide dismutase (SOD), and malondialdehyde (MDA). To achieve the study objectives, 32 male Wistar Albino rats were assigned to four different groups. The control group received physiological saline for six weeks. The haloperidol group received 1 mg/kg/ip haloperidol for the first three weeks, followed by two weeks of saline. The haloperidol+fluvoxamine group received 1 mg/kg/ip haloperidol for the first three weeks, followed by 30 mg/kg/ip fluvoxamine. The haloperidol+tetrabenazine group was administered 1 mg/kg/ip haloperidol for the first three weeks, followed by 5 mg/kg/ip tetrabenazine. Behavioral assessments of the rats were performed by measuring vacuous chewing movements. Subsequently, samples were collected from the hippocampus, striatum, and frontal lobe tissues of the rats, and BDNF, NGF, SOD, and MDA levels were measured. The results of the study demonstrated significant differences between the groups with respect to behavioral observations. Furthermore, SOD levels in the hippocampus, as well as BDNF, NGF, and SOD levels in the striatum of the haloperidol+fluvoxamine group were significantly higher than those observed in the haloperidol group. Conversely, MDA levels in the hippocampus were significantly lower in the haloperidol+fluvoxamine group than in the haloperidol group. These findings provide evidence of the beneficial effects of fluvoxamine, acting as a sigma-1 agonist, in treating TD symptoms induced experimentally. The observed benefits were supported by the biochemical investigations performed on brain tissue samples. Therefore, fluvoxamine may be considered as a potential alternative treatment for TD in clinical practice, although further research is needed to corroborate these findings." @default.
• W4377011619 created "2023-05-19" @default.
• W4377011619 creator A5034868535 @default.
• W4377011619 creator A5074365284 @default.
• W4377011619 creator A5088414432 @default.
• W4377011619 creator A5089355925 @default.
• W4377011619 creator A5091971039 @default.
• W4377011619 date "2023-08-01" @default.
• W4377011619 modified "2023-09-30" @default.
• W4377011619 title "The effects of sigma-1 agonist fluvoxamine on experimental induced tardive dyskinesia model in rats" @default.
• W4377011619 cites W1548283165 @default.
• W4377011619 cites W1559350916 @default.
• W4377011619 cites W1966195483 @default.
• W4377011619 cites W1970705129 @default.
• W4377011619 cites W1975167087 @default.
• W4377011619 cites W1981236667 @default.
• W4377011619 cites W2016354522 @default.
• W4377011619 cites W2025149917 @default.
• W4377011619 cites W2043387126 @default.
• W4377011619 cites W2053052689 @default.
• W4377011619 cites W2064678154 @default.
• W4377011619 cites W2084477006 @default.
• W4377011619 cites W2091828873 @default.
• W4377011619 cites W2112286580 @default.
• W4377011619 cites W2113902650 @default.
• W4377011619 cites W2123950263 @default.
• W4377011619 cites W2139286771 @default.
• W4377011619 cites W2152862617 @default.
• W4377011619 cites W2319946110 @default.
• W4377011619 cites W2474394086 @default.
• W4377011619 cites W2597065179 @default.
• W4377011619 cites W2791129224 @default.
• W4377011619 cites W2791987476 @default.
• W4377011619 cites W2800606606 @default.
• W4377011619 doi "https://doi.org/10.1016/j.pnpbp.2023.110787" @default.
• W4377011619 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37196751" @default.
• W4377011619 hasPublicationYear "2023" @default.
• W4377011619 type Work @default.
• W4377011619 citedByCount "0" @default.
• W4377011619 crossrefType "journal-article" @default.
• W4377011619 hasAuthorship W4377011619A5034868535 @default.
• W4377011619 hasAuthorship W4377011619A5074365284 @default.
• W4377011619 hasAuthorship W4377011619A5088414432 @default.
• W4377011619 hasAuthorship W4377011619A5089355925 @default.
• W4377011619 hasAuthorship W4377011619A5091971039 @default.
• W4377011619 hasConcept C118552586 @default.
• W4377011619 hasConcept C126322002 @default.
• W4377011619 hasConcept C15744967 @default.
• W4377011619 hasConcept C170493617 @default.
• W4377011619 hasConcept C2775864247 @default.
• W4377011619 hasConcept C2776134451 @default.
• W4377011619 hasConcept C2776284327 @default.
• W4377011619 hasConcept C2776412080 @default.
• W4377011619 hasConcept C2778938600 @default.
• W4377011619 hasConcept C2779134260 @default.
• W4377011619 hasConcept C2779158372 @default.
• W4377011619 hasConcept C2779734285 @default.
• W4377011619 hasConcept C2779910183 @default.
• W4377011619 hasConcept C2780405171 @default.
• W4377011619 hasConcept C2780494398 @default.
• W4377011619 hasConcept C2780948584 @default.
• W4377011619 hasConcept C42219234 @default.
• W4377011619 hasConcept C513476851 @default.
• W4377011619 hasConcept C71924100 @default.
• W4377011619 hasConcept C98274493 @default.
• W4377011619 hasConceptScore W4377011619C118552586 @default.
• W4377011619 hasConceptScore W4377011619C126322002 @default.
• W4377011619 hasConceptScore W4377011619C15744967 @default.
• W4377011619 hasConceptScore W4377011619C170493617 @default.
• W4377011619 hasConceptScore W4377011619C2775864247 @default.
• W4377011619 hasConceptScore W4377011619C2776134451 @default.
• W4377011619 hasConceptScore W4377011619C2776284327 @default.
• W4377011619 hasConceptScore W4377011619C2776412080 @default.
• W4377011619 hasConceptScore W4377011619C2778938600 @default.
• W4377011619 hasConceptScore W4377011619C2779134260 @default.
• W4377011619 hasConceptScore W4377011619C2779158372 @default.
• W4377011619 hasConceptScore W4377011619C2779734285 @default.
• W4377011619 hasConceptScore W4377011619C2779910183 @default.
• W4377011619 hasConceptScore W4377011619C2780405171 @default.
• W4377011619 hasConceptScore W4377011619C2780494398 @default.
• W4377011619 hasConceptScore W4377011619C2780948584 @default.
• W4377011619 hasConceptScore W4377011619C42219234 @default.
• W4377011619 hasConceptScore W4377011619C513476851 @default.
• W4377011619 hasConceptScore W4377011619C71924100 @default.
• W4377011619 hasConceptScore W4377011619C98274493 @default.
• W4377011619 hasLocation W43770116191 @default.
• W4377011619 hasLocation W43770116192 @default.
• W4377011619 hasOpenAccess W4377011619 @default.
• W4377011619 hasPrimaryLocation W43770116191 @default.
• W4377011619 hasRelatedWork W1683267574 @default.
• W4377011619 hasRelatedWork W1950648568 @default.
• W4377011619 hasRelatedWork W1965252147 @default.
• W4377011619 hasRelatedWork W1979258932 @default.
• W4377011619 hasRelatedWork W2035278173 @default.
• W4377011619 hasRelatedWork W2049260133 @default.
• W4377011619 hasRelatedWork W2182701448 @default.
• W4377011619 hasRelatedWork W2546593550 @default.
• W4377011619 hasRelatedWork W2943826158 @default.

• next